Cargando…

Clinical, dermoscopic, and ultrasonic monitoring of the response to biologic treatment in patients with moderate-to-severe plaque psoriasis

BACKGROUND: Assessment of therapeutic response of psoriasis has relied traditionally on clinical observation, and effective non-invasive tools are desirable. OBJECTIVES: To investigate the value of dermoscopy and high-frequency ultrasound (HFUS) in the monitoring of psoriatic lesions treated with bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Juncheng, Zhu, Qingli, Li, Feng, Xiao, Mengsu, Liu, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10330810/
https://www.ncbi.nlm.nih.gov/pubmed/37435540
http://dx.doi.org/10.3389/fmed.2023.1162873
_version_ 1785070153692610560
author Wang, Juncheng
Zhu, Qingli
Li, Feng
Xiao, Mengsu
Liu, Jie
author_facet Wang, Juncheng
Zhu, Qingli
Li, Feng
Xiao, Mengsu
Liu, Jie
author_sort Wang, Juncheng
collection PubMed
description BACKGROUND: Assessment of therapeutic response of psoriasis has relied traditionally on clinical observation, and effective non-invasive tools are desirable. OBJECTIVES: To investigate the value of dermoscopy and high-frequency ultrasound (HFUS) in the monitoring of psoriatic lesions treated with biologics. METHODS: Patients with moderate-to-severe plaque psoriasis treated with biologics were evaluated by clinical, dermoscopic, and ultrasonic scores at weeks 0, 4, 8, and 12. Clinical scores, including Psoriasis Area Severity Index (PASI) and target lesion score (TLS), were evaluated at representative lesions. Dermoscopy was performed to assess the red background, vessels, and scales on a 4-point scale as well as the presence of hyperpigmentation, hemorrhagic spots, and linear vessels. HFUS was performed to measure the thicknesses of the superficial hyperechoic band and subepidermal hypoechoic band (SLEB). The correlation between clinical, dermoscopic, and ultrasonic evaluation was also analyzed. RESULTS: In total, 24 patients were analyzed and achieved 85.3 and 87.5% reduction of PASI and TLS, respectively, after 12 weeks of treatment. The red background, vessels, and scales scores under dermoscopy were reduced by 78.5, 84.1, and 86.5%, respectively. Some patients developed hyperpigmentation and linear vessels after treatment. Hemorrhagic dots slowly subside over the therapeutic course. Ultrasonic scores were significantly improved with an average reduction of 53.9% in superficial hyperechoic band thickness and 89.9% in SLEB thickness. TLS in the clinical variables, scales in dermoscopic variables, and SLEB in ultrasonic variables decreased the most significantly in the early stage of treatment (week 4) with 55.4, 57.7, and 59.1% (P > 0.05), respectively. Most of the variables, including the red background, vessels, scales, and SLEB thickness, were strongly correlated with TLS. High correlations were also found between the SLEB thickness and the red background or vessels scores, and between the superficial hyperechoic band thickness and the scales scores. CONCLUSION: Both dermoscopy and HFUS were useful in the therapeutic monitoring of moderate-to-severe plaque psoriasis.
format Online
Article
Text
id pubmed-10330810
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103308102023-07-11 Clinical, dermoscopic, and ultrasonic monitoring of the response to biologic treatment in patients with moderate-to-severe plaque psoriasis Wang, Juncheng Zhu, Qingli Li, Feng Xiao, Mengsu Liu, Jie Front Med (Lausanne) Medicine BACKGROUND: Assessment of therapeutic response of psoriasis has relied traditionally on clinical observation, and effective non-invasive tools are desirable. OBJECTIVES: To investigate the value of dermoscopy and high-frequency ultrasound (HFUS) in the monitoring of psoriatic lesions treated with biologics. METHODS: Patients with moderate-to-severe plaque psoriasis treated with biologics were evaluated by clinical, dermoscopic, and ultrasonic scores at weeks 0, 4, 8, and 12. Clinical scores, including Psoriasis Area Severity Index (PASI) and target lesion score (TLS), were evaluated at representative lesions. Dermoscopy was performed to assess the red background, vessels, and scales on a 4-point scale as well as the presence of hyperpigmentation, hemorrhagic spots, and linear vessels. HFUS was performed to measure the thicknesses of the superficial hyperechoic band and subepidermal hypoechoic band (SLEB). The correlation between clinical, dermoscopic, and ultrasonic evaluation was also analyzed. RESULTS: In total, 24 patients were analyzed and achieved 85.3 and 87.5% reduction of PASI and TLS, respectively, after 12 weeks of treatment. The red background, vessels, and scales scores under dermoscopy were reduced by 78.5, 84.1, and 86.5%, respectively. Some patients developed hyperpigmentation and linear vessels after treatment. Hemorrhagic dots slowly subside over the therapeutic course. Ultrasonic scores were significantly improved with an average reduction of 53.9% in superficial hyperechoic band thickness and 89.9% in SLEB thickness. TLS in the clinical variables, scales in dermoscopic variables, and SLEB in ultrasonic variables decreased the most significantly in the early stage of treatment (week 4) with 55.4, 57.7, and 59.1% (P > 0.05), respectively. Most of the variables, including the red background, vessels, scales, and SLEB thickness, were strongly correlated with TLS. High correlations were also found between the SLEB thickness and the red background or vessels scores, and between the superficial hyperechoic band thickness and the scales scores. CONCLUSION: Both dermoscopy and HFUS were useful in the therapeutic monitoring of moderate-to-severe plaque psoriasis. Frontiers Media S.A. 2023-06-26 /pmc/articles/PMC10330810/ /pubmed/37435540 http://dx.doi.org/10.3389/fmed.2023.1162873 Text en Copyright © 2023 Wang, Zhu, Li, Xiao and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Wang, Juncheng
Zhu, Qingli
Li, Feng
Xiao, Mengsu
Liu, Jie
Clinical, dermoscopic, and ultrasonic monitoring of the response to biologic treatment in patients with moderate-to-severe plaque psoriasis
title Clinical, dermoscopic, and ultrasonic monitoring of the response to biologic treatment in patients with moderate-to-severe plaque psoriasis
title_full Clinical, dermoscopic, and ultrasonic monitoring of the response to biologic treatment in patients with moderate-to-severe plaque psoriasis
title_fullStr Clinical, dermoscopic, and ultrasonic monitoring of the response to biologic treatment in patients with moderate-to-severe plaque psoriasis
title_full_unstemmed Clinical, dermoscopic, and ultrasonic monitoring of the response to biologic treatment in patients with moderate-to-severe plaque psoriasis
title_short Clinical, dermoscopic, and ultrasonic monitoring of the response to biologic treatment in patients with moderate-to-severe plaque psoriasis
title_sort clinical, dermoscopic, and ultrasonic monitoring of the response to biologic treatment in patients with moderate-to-severe plaque psoriasis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10330810/
https://www.ncbi.nlm.nih.gov/pubmed/37435540
http://dx.doi.org/10.3389/fmed.2023.1162873
work_keys_str_mv AT wangjuncheng clinicaldermoscopicandultrasonicmonitoringoftheresponsetobiologictreatmentinpatientswithmoderatetosevereplaquepsoriasis
AT zhuqingli clinicaldermoscopicandultrasonicmonitoringoftheresponsetobiologictreatmentinpatientswithmoderatetosevereplaquepsoriasis
AT lifeng clinicaldermoscopicandultrasonicmonitoringoftheresponsetobiologictreatmentinpatientswithmoderatetosevereplaquepsoriasis
AT xiaomengsu clinicaldermoscopicandultrasonicmonitoringoftheresponsetobiologictreatmentinpatientswithmoderatetosevereplaquepsoriasis
AT liujie clinicaldermoscopicandultrasonicmonitoringoftheresponsetobiologictreatmentinpatientswithmoderatetosevereplaquepsoriasis